Ei.Ventures, Inc. (EVI) entered into a letter of interest to acquire Mycotopia Therapies Inc. (OTCPK:TPIA) (MTI) in a reverse merger transaction for $360 million on December 7, 2021. Mycotopia Therapies Inc. entered into an Agreement and Plan of Merger to acquire Ei.Ventures, Inc. for $360 million on May 18, 2022. At closing each share of common stock of MTI shall be converted into the right to receive 0.25 fully paid and nonassessable share of PSLY.com Common Stock. At Closing each share of common stock of EVI will be convertible into the right receive a number of PSLY.com Common Stock equal to (i) the sum of $360,000,000 (Three Hundred Sixty Million Dollars) (ii) divided by $1.56, the result of which is divided by (iii) the product of the total number of shares of EVI Common Stock then issued and outstanding times four (4). When a definitive agreement is reached, the combined companies intend to pool their resources to develop regulatory approved, plant-derived, psychoactive therapeutic treatment options and non-psychoactive nutritional supplements and related products that address global mental healthcare needs. In the event that transaction is terminated by MTI or EVI, terminating party will pay a $2 million termination fee. At closing David Nikzad and Jason A. Hobson would be appointed as officers and directors of the combined company and the combined company would change its name to PSLY.COM, to better reflect the Company's business moving forward. The Company plans to use PSLY as its trading symbol.

Transaction is subject to EVI and MTI shareholders approval and government consents. EVI and MTI board unanimously recommended the transaction to their shareholders. The parties expect any transaction would close in the first quarter of 2022. The companies anticipate closing the transaction on or about July 30, 2022. Greg Giammittorio of Potomac Law Group PLLC acted as legal advisor to Ei.Ventures, Inc. Jonathan D Leinwand P A acted as legal advisor for Mycotopia.